🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Actinium Pharmaceuticals, Inc. ATNM PHARMA

Healthcare · Biotechnology · United States
https://www.actiniumpharma.com
Company Profile ↓
$1.23
-28.90% 1Y
Mkt Cap$38.59M
P/E3.51
P/B1.28
52W High$1.73
52W Low$0.75
Book Value$0.96
EPS (TTM)$0.35

Company Overview

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 45.9%, reflecting efficient use of shareholder capital.

Reasonable Valuation

Trades at a P/E of 3.5, below the sector median of 24.8.

Healthy Margins

Maintains a net profit margin of 32.2%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Trailing 12 Months Year-on-year growth — revenue +11.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-
1 Year:11.11%

Stock Price Performance

1 Year:-28.90%
6 Months:+2.50%
3 Months:+16.04%
1 Month:+54.33%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 49% of range
$0.75 $1.73
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)70.98 · Overbought
Price Performance
1M+54.33%
3M+16.04%
6M+2.50%
1Y-28.90%
Valuation vs Sector

P/E of 3.51 is below the sector median of 24.83 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 45.9%.
  • Excellent profit margin of 32.2%.
  • Generates positive free cash flow.

CONS

  • Trading 28.9% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
3.51
Industry PE
24.83
Forward P/E
-2.34
PEG Ratio
-
Book Value
$0.96
Price to Book
1.28
P/S
1.10
EV/EBITDA
0.36
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
11.11%
Earnings (YoY)
-

Profitability & Returns

ROCE
-82.74%
ROE
45.86%
ROA
11.58%
Profit Margin
32.23%
Op Margin
78.76%
Gross Margin
100.00%
EPS (Latest Qtr)
$0.89
EPS (TTM)
$0.35

Balance Sheet & Liquidity

Debt/Equity
4.42
Quick Ratio
3.94
Current Ratio
4.08
Debt
$1.34M
Total Assets
$40.16M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
9.83%
Chg in Prom Hold
1.37%
FII / Inst Holding
20.52%
Chg in FII Hold
-0.01%

Financial Snapshot

Enterprise Value
$38.59M
Total Revenue (TTM)
$35.09M
EBITDA
$9.79M
Free Cash Flow
$7.14M
Operating Cash Flow
$-22.66M
Shares Outstanding
31.37M
Gross Margin
100.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ATNM Actinium Pharmaceuticals, Inc. PHARMA 1.23 3.51 $38.59M 0.00% -82.74% 45.86% - -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jun 2013Sep 2013Mar 2014Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026Jun 2026
Revenue -----------------------622.00K266.00K233.00K940.00K45.00K45.00K--------90.00K-35.00M
Operating Income -1.48M-1.61M-4.14M-4.42M-7.04M-7.87M-7.40M-4.64M-6.00M-6.92M-7.10M-7.81M-7.20M-6.70M-6.35M-4.91M-6.20M-5.70M-5.09M-6.65M-5.68M-4.66M-5.61M-5.37M-5.08M-6.47M-5.16M-7.85M-9.80M-11.58M-15.64M-14.35M-9.60M-12.42M-12.60M-16.64M-7.50M-5.69M-5.90M27.57M
Net Income -2.78M-1.42M-16.70M3.52M-6.08M-3.07M-7.46M-3.95M-4.40M-6.62M-6.60M-8.06M-7.05M-6.32M-6.32M-4.86M-6.15M-5.67M-5.03M-6.60M-5.67M-4.62M-5.54M-5.32M-5.02M-6.42M-5.13M-7.77M-9.47M-11.04M-15.18M-13.28M-8.67M-11.35M-11.57M-15.94M-6.88M-5.13M-5.52M27.90M
Diluted EPS -0.13--0.10---0.20-0.10--0.15-0.14--------------0.25-0.30-0.23-0.33-0.38-0.43-0.58-0.49-0.31-0.38-0.37-0.51-0.22-0.16-0.180.89
R&D Expense 509.26K778.23K1.59M2.13M4.14M4.05M3.84M2.83M3.77M4.15M5.69M4.57M4.45M5.03M4.47M3.33M4.23M4.34M4.01M4.83M4.15M3.51M3.79M4.28M3.63M4.71M4.37M4.66M6.77M7.85M11.08M11.62M6.63M8.82M9.77M7.70M4.88M4.25M4.20M5.38M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2001Dec 2002Dec 2003Dec 2004Dec 2005Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue ---------00---------1.14M1.03M81.00K-90.00K
Gross Profit ---------00--------------
Operating Income ----------26.05K-3.28M-7.95M-6.59M-22.48M-24.83M-26.85M-26.91M-23.83M-22.07M-22.39M-24.96M-34.10M-51.92M-42.12M-36.25M
Net Income -5.09M-3.19M-3.53M-5.73M-4.58M-6.05M-5.62M-5.57M-3.43M-467.27K-3.44M-8.36M-10.77M-24.69M-21.03M-24.32M-26.60M-23.65M-21.90M-22.21M-24.77M-33.02M-48.82M-38.24M-33.89M
Diluted EPS ---------------------1.20-1.37-1.83-1.27-1.09
R&D Expense ----------323.79K3.44M3.11M12.27M13.50M17.83M17.72M17.09M16.55M16.09M18.03M23.14M38.67M30.05M21.12M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2000Dec 2001Dec 2002Dec 2003Dec 2004Dec 2005Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets ----------1506.20M5.79M5.77M7.57M26.59M22.53M18.34M14.89M11.67M66.40M80.39M114.19M81.44M76.90M51.77M
Total Equity 1.11M-1.73M-1.68M1.57M439.12K74.28K1.82M3.46M4.16M845.16K399.06K992.01K1.15M-1.56M-1.92M21.97M18.01M13.67M8.81M5.64M61.32M73.55M66.48M36.38M32.76M7.83M
Cash & Equivalents ---------2.12K196.13K5.70M5.62M5.53M6.71M25.64M20.52M17.40M13.67M9.25M63.56M77.83M108.91M76.68M72.90M48.00M
Total Liabilities ----------94.77K84.48K4.64M7.33M9.49M4.61M4.52M4.67M6.08M6.03M5.08M6.84M47.71M45.07M44.14M43.94M
Current Liabilities ----------36.06K5.21M4.64M7.33M9.49M4.61M4.52M4.67M6.06M5.34M4.77M6.84M10.63M8.49M8.15M7.97M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 7.83K-517.59K-5.21M-6.29M-14.35M-18.54M-20.79M-21.55M-20.57M-21.46M-21.62M-20.87M8.64M-47.34M-33.07M-24.58M
Investing Cash Flow 00-2.36K-16.59K-186.42K-47.79K-109.82K-24.74K-96.09K-64.00K-253.00K-133.00K-366.00K-153.00K-11.00K-104.00K
Financing Cash Flow -9.81K6.03M5.13M6.22M15.71M37.53M15.78M18.81M16.98M17.11M76.18M35.22M23.11M14.87M29.32M-217.00K
Capital Expenditure ---2.36K-16.59K-151.69K-47.79K-59.96K-24.74K-96.09K-64.00K-253.00K-133.00K-366.00K-153.00K-11.00K-104.00K
Free Cash Flow ---5.22M-6.31M-14.50M-18.59M-20.85M-21.58M-20.67M-21.53M-21.87M-21.00M8.28M-47.49M-33.08M-24.68M

Ratios (Annual)

Figures in %.

Metric Dec 2001Dec 2002Dec 2003Dec 2004Dec 2005Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------------------------
Operating Margin % ---------------------2,182.2%-3,311.1%-64,098.8%--40,274.4%
Net Margin % ---------------------2,165.6%-3,205.5%-60,269.1%--37,652.2%
ROE % 293.8%190.6%-224.4%-1,306.0%-6,166.6%-331.9%-162.4%-134.0%-405.4%-117.1%-347.3%-729.8%690.8%1,284.1%-95.7%-135.1%-194.6%-268.4%-388.0%-36.2%-33.7%-49.7%-134.2%-116.7%-432.6%
ROCE % ---------72.5%-331.0%-693.7%422.7%1,169.3%-113.0%-149.1%-196.8%-270.0%-348.9%-36.3%-33.9%-32.9%-71.2%-61.3%-82.7%

Shareholding Pattern

Insiders
9.83%
Institutions
20.52%
Public Float
22.76%

Top Institutional Holders

#Holder% HeldSharesValue
1 Vanguard Capital Management LLC 3.94% 1.24M $1.51M
2 Compass Financial Management LLC 1.91% 600.23K $732.28K
3 Millennium Management Llc 1.64% 514.58K $627.79K
4 Acadian Asset Management. LLC 1.58% 496.29K $605.47K
5 Blackrock Inc. 1.26% 395.90K $482.99K
6 Renaissance Technologies, LLC 1.21% 380.49K $464.20K
7 Geode Capital Management, LLC 1.03% 324.94K $396.43K
8 Two Sigma Investments, LP 0.82% 259.18K $316.20K
9 Gagnon Securities, LLC 0.58% 182.14K $222.21K
10 Vanguard Fiduciary Trust Co 0.51% 161.53K $197.06K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ATNM

Google News Fri, 04 Sep 2026

A radiotherapy company’s CEO will speak in New York Sept. 14. - Stock Titan

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPOGZUX25pS1czbXFVeTNQc1BaZURmVW9FYkVUR3ExeWVINE5RU3owTUdZV0dHVkFzOC0tZWQzbldWbF9HeHhTWjQwNGl2UXlTQnhqNTYwRF9RNnM0bnIyTUZEc2s2UU5USWprSkdCMnoxTXg1eGZrWDVsMG1JZGc4aGZvSVhPdnJLN1EzT2…

Google News Fri, 04 Sep 2026

Actinium Pharmaceuticals (ATNM) grants director new stock awards - Stock Titan

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOMkw4bWsxS1hURFdtVmZTSzJUVnNQLXp4cV94QlM3ZEtfc21ZNWFMVFVqd3JLNVowdkxXYmR6aDlPdUo2UWF0UmZZamI0S1VSTVdneno0aXZqYWhUUFVrWkZpcHdlRzVsYWQ3RGF3WjhvdnZqbjh2dXI5a0kyaHhBTjJvNi1rTnlhWWZ4UF…

Google News hu, 28 May 2026

ATNM - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE42RVBlMmhzanY5Vmx5eXBfeWREd3VvVU4tSkVscnFGMi1vbGxJVDdLQURfWXhHNDc3UWR6VDAtMVB4MXA5bnc?oc=5" target="_blank">ATNM</a>&nbsp;&nbsp;<font color="#6f6f6f">Finviz</font>…

Google News Sat, 14 Feb 2026

ATNM Should I Buy - Intellectia AI

<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE1kNjljWFRLcXRGLUI0ZFZkS3dzcG9IVExBTE9FTTNsX0VwdVFiYXVabmRqdnlHOGFWeENFZExaOFN1MXZ2RHFtSzR1TGpaQm4zNVdnOUJOaklXVTVEVlE?oc=5" target="_blank">ATNM Should I Buy</a>&nbsp;&nbsp;<font c…

Google News Mon, 20 Apr 2026

SLS Vs ATNM: Which Cancer Stock Has Bigger Upside Ahead Of Fresh Data Reveal? - Stocktwits

<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxQSzF0LXF1azRaT2R6Q2w2dHg0Tkg2UXJMUGRoZE5TUWJSdUJvaUJkR0NLWDlWaXROUThwY05rdXZjZGhaQ2tGYmp0Q3pYdzFrMkJyNURNZTJvQWlTa1g2N291cTZSa2ZmR1JtMjA3RXhMYnU2SWtsbHN4S184UzZXTHNDZjh2RngwQjcyUG…

Google News Mon, 17 Nov 2025

The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet - TMX Newsfile

<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxNdVVhOEk4UE03NW1Ednk5ZElhZXVQbGl1SDd4XzBFaGd6bXBHcDdoVW5wVmpQNWIzblo2ZERZZ08wcmYwRzJ0N2xCOEdEelpCTjU5Y0tBeVEwM0xfZ3VwbXFvRTFPa3RIeEFlQUthX0g4TmVBRkVOZndqaWV6MXRGT1lIQ29sbnNack85eG…

ATNM — Frequently Asked Questions

What is the current share price of Actinium Pharmaceuticals, Inc. (ATNM)?

As of 2026-09-19 21:16 PDT, Actinium Pharmaceuticals, Inc. (ATNM) trades at $1.23 on NYSE American. Its 52-week range is $0.75 to $1.73.

What is the market capitalisation of ATNM?

Actinium Pharmaceuticals, Inc. (ATNM) has a market capitalisation of $38.59M on NYSE American.

What is the P/E ratio of ATNM?

ATNM trades at a trailing price-to-earnings (P/E) ratio of 3.51. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.28.

What is the return on equity (ROE) of ATNM?

ATNM has a return on equity (ROE) of 45.86%. Its return on capital employed (ROCE) is -82.74%.

Is ATNM a good stock to buy?

This page provides a data-driven analysis of Actinium Pharmaceuticals, Inc. (ATNM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space